The staggering death toll of scientific lies

Role of Science, Trust, and Individual Choice

• Several comments argue that people should not be compelled to “follow the science” as if it had inherent moral authority; individuals should retain autonomy over medical decisions.
• Others counter that complex modern systems (medicine, water, food) necessarily rely on expert institutions and trust; laypeople can’t independently verify most claims.
• There is concern that “freedom” is often confused with freedom from consequences (e.g., job loss, school exclusion, travel limits).

Vaccines, Risk, and Mandates

• One side stresses that vaccines greatly reduced Covid deaths, that disease risk far outweighs vaccine risk, and that limiting exposure to unvaccinated people is a legitimate societal interest.
• Another side points to documented vaccine side effects, specific death cases, and lack of strong transmission-blocking, questioning the justification for mandates if spread isn’t fully prevented.
• Some argue that overstated or false official claims (“zero risk,” full transmission prevention) and censorship erode trust and fuel skepticism.

Liability and Criminalization of Scientific Fraud

• Many support treating willful data fabrication that leads to deaths as akin to manslaughter or fraud, warranting criminal penalties.
• Others warn that liability will chill honest research, is hard to adjudicate (distinguishing fraud vs. error), and could shift blame away from guideline-setters and clinicians.
• Debate over whether responsibility lies more with fraudulent researchers or with institutions that embed fragile, single-study results into guidelines.

Systemic Problems: Replication, Incentives, and Quality

• Widespread concerns about poor statistics, p‑hacking, weak standards in some medical, psychological, and social sciences; physics is seen by some as more rigorous.
• Replication is underfunded, unrewarded, and often absent; citation chains progressively oversimplify nuanced results.
• Suggestions: mandatory replication funding quotas, required citation of replication outcomes, better stats education, detailed record‑keeping with audits, and possibly financial bonding for published results (though many see bonding as costly and exclusionary).

Case-Specific Issues: Beta Blockers and Guidelines

• Commenters note that the huge “death toll” estimate rests on guideline adoption of flawed studies and possibly on a few dominant trials, some themselves partly tainted by fraud.
• Others emphasize that “not acting” is also a choice: clinicians must decide under uncertainty, and trusting the best available (even imperfect) evidence may still minimize harm overall.